SAN DIEGO, CA–(Marketwired – November 23, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA) announced today that Newsweek featured its subsidiary HempMeds® Mexico’s non-psychoactive, THC-free hemp-based cannabidiol (CBD) product Real Scientific Hemp Oil-X™ (RSHO-X™), the first-ever federally approved CBD product in Mexico, in an Oct. 24 cover story.
The Newsweek cover story titled, “Fiebre por el cannabis,” outlines the legal status of cannabis in Mexico, California’s burgeoning marijuana market, and how HempMeds® Mexico‘s THC-free RSHO-X™ became the first-ever product approved for import by the Mexico government to treat an adolescent girl suffering from epilepsy. The article also highlights how demand for the Company’s RSHO-X™ is increasing across the Country to treat various medical indications and Medical Marijuana, Inc.’s expansion across Latin America, which according to the Company’s Chief Executive Officer Dr. Stuart Titus will bring the Company “a good stretch of economic growth.”
Medical Marijuana, Inc. also announced that its subsidiary HempMeds® Mexico has opened a new office in Monterey, Mexico, which will serve as the Company’s hub for the sales, marketing and distribution of RSHO-X™ to distributors and patients in Mexico. HempMeds® Mexico also continues to bring on new leadership, most recently with the addition of a new Chief Operating Officer (COO) Carlos Gonzales, who will be responsible of the operation in increase sales and promote distribution processes for the products of the company, particularly RSHO-X™.
“This new office opening is exciting, as our Company will now be operating on the ground in Mexico, which will help further our already established relationship with the Mexico government, as we continue working to educate local health officials and lawmakers on the benefits of CBD hemp oil and help patients learn how to access RSHO-X™ for themselves,” said Chief Executive Officer of Medical Marijuana, Inc. Dr. Stuart Titus. “We’re also thrilled to have Carlos join the team in Mexico and are confident in his ability to support Mexican families who need access to cannabidiol products, which have helped in treating neurological conditions such as refractory epilepsy and diabetic neuropathy. Over time, our research may lead us into further neurological, neuro-degenerative disorders.”
RSHO-X™ was also recently approved by the Mexico government COFEPRIS for the first time to assist in the treatment of neuropathic conditions related with diabetes. HempMeds® Mexico is also dedicated to continuing educating health professionals, government officials and patients across the country about the benefits of CBD. To this end, the Company held the first-ever First National Symposium on Medical Cannabis, an event dedicated to providing the medical community with information about the medical value of CBD derivatives in Mexico City on Oct. 8. The Company also recently participated in exhibition “Hemp For All,” which was held in the Mexican Senate, to help advocate for the legalization of medicinal cannabis in Mexico to Mexican lawmakers.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC-MJNA (888-682-6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500